A randomized trial comparing @entity1499 and @entity5713 (MV) with @entity900 , @entity1499 and @entity5713 ( @entity2834 ) in advanced XXXX : results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party.

@entity1 @entity137 @entity900 @entity1606 @entity3 @entity2834 @entity1499 @entity5713
@entity1606 may arise at any site within the urinary tract and are a source of considerable morbidity and mortality. In particular, @entity1 with @entity3 have a poor prognosis, with less than 5% alive at 5 years. A multicentre randomized trial comparing @entity1499 and @entity5713 (MV) with @entity900 , @entity1499 and @entity5713 ( @entity2834 ) in advanced or metastatic @entity1606 was conducted in the UK. From April 1991 to June 1995, 214 @entity1 were entered by 16 centres, 108 randomized to @entity2834 and 106 to MV. A total of 204 @entity1 have died. The hazard ratio (relative risk of dying) was 0.68 (95% CI 0.51-0.90, P-value = 0.0065) in favour of @entity2834 . This translates to an absolute improvement in 1-year survival of 13%, 16% in MV and 29% in @entity2834 . The median survival for @entity2834 and MV was 7 months and 4.5 months respectively. Two hundred and eight @entity1 objectively progressed or died. The hazard ratio was 0.55 (95% CI 0.41-0.73, P-value = 0.0001) in favour of @entity2834 . Two hundred and nine @entity1 symptomatically progressed or died. The hazard ratio was 0.48 (95% CI 0.36-0.64, P-value = 0.0001) in favour of @entity2834 . The most important pretreatment factors influencing overall survival were WHO performance status and extent of disease. These two factors were used to derive a prognostic index which could be used to categorize @entity1 into three prognostic groups. We conclude that the addition of @entity900 to @entity1499 and @entity5713 should be considered in @entity1 with @entity1606 , taking into account the increased @entity137 .
